TOT BIOPHARM International Co. Ltd., in partnership with BioDlink and Lepu Biopharma, has announced the successful regulatory approval and launch of MEIYOUHENG®, the world's first EGFR-targeting ADC drug. The product received marketing approval from China's National Medical Products Administration (NMPA) on October 30, 2025. This milestone marks the first time an antibody-drug conjugate $(ADC)$ fully manufactured by a contract development and manufacturing organization $(CDMO)$ has reached the market in China, highlighting significant progress in the region's biopharmaceutical sector. The achievement underscores the robust collaboration and operational excellence among the involved organizations throughout the development, technology transfer, and manufacturing process.